Search research articles
Contact Us
Filters
Showing results (71-80 of 87) with videos related to
Page
of 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape
D J Vis, J Lewin, R G Liao, et al.
British Journal of Cancer
|
July 19, 2012
A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
I Diaz-Padilla, L L Siu, M San Pedro-Salcedo, et al.
British Journal of Cancer
|
June 2, 2011
Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy
C R Garrett, L L Siu, A El-Khoueiry, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2012
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
A R Abdul Razak, D Soulières, S A Laurie, et al.
British Journal of Cancer
|
December 17, 2013
Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer
D J Jonker, C S Karapetis, C Harbison, et al.
British Journal of Cancer
|
October 8, 2014
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
I Brana, R Berger, T Golan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2018
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials
Y Kanjanapan, D Day, M O Butler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 2, 2023
First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)
A Spreafico, A A Heirali, D V Araujo, et al.
Current Oncology (Toronto, Ont.)
|
November 12, 2019
OCTANE (Ontario-wide Cancer Targeted Nucleic Acid Evaluation): a platform for intraprovincial, national, and international clinical data-sharing
E R Malone, R R Saleh, C Yu, et al.
British Journal of Cancer
|
July 23, 2013
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)
S Sahebjam, P L Bedard, V Castonguay, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 87) with videos related to
Sort By:
Page
of 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape
D J Vis, J Lewin, R G Liao, et al.
British Journal of Cancer
|
July 19, 2012
A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
I Diaz-Padilla, L L Siu, M San Pedro-Salcedo, et al.
British Journal of Cancer
|
June 2, 2011
Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy
C R Garrett, L L Siu, A El-Khoueiry, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2012
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
A R Abdul Razak, D Soulières, S A Laurie, et al.
British Journal of Cancer
|
December 17, 2013
Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer
D J Jonker, C S Karapetis, C Harbison, et al.
British Journal of Cancer
|
October 8, 2014
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
I Brana, R Berger, T Golan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2018
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials
Y Kanjanapan, D Day, M O Butler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 2, 2023
First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)
A Spreafico, A A Heirali, D V Araujo, et al.
Current Oncology (Toronto, Ont.)
|
November 12, 2019
OCTANE (Ontario-wide Cancer Targeted Nucleic Acid Evaluation): a platform for intraprovincial, national, and international clinical data-sharing
E R Malone, R R Saleh, C Yu, et al.
British Journal of Cancer
|
July 23, 2013
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)
S Sahebjam, P L Bedard, V Castonguay, et al.
Page
of 9